Futu News reported on May 23,$SUNHO BIO-B (02898.HK)$Today's dark market opened higher, closing up 8.15% to HK$14.60, with a turnover of HK$1,987 million, with a total market value of HK$2,287 billion; 200 shares per lot, without handling fees, earned HK$220 per lot.
Market Source: Futu Securities Securities>
Investment highlights
Independent development of antibody cytokines: According to Frost & Sullivan data, the company is in a leading position in exploring antibody cytokines that regulate the immune microenvironment, and has rich technical experience. Advantages of antibody cytokines: The sequence, spatial structure, and protein modification are exquisitely designed, so that cytokines achieve a better balance in safety and efficacy, and overcome the defects of cytokines as a double-edged sword in regulating the immune system. Currently, the company's antibody cytokine pipeline products include IAP0971, IAEO972, and IBB0979. All three antibody cytokines have received IND approval from the US FDA and China National Drug Administration. All three products are in phase I/II clinical phase.
The core product market prospects are broad: the company's IAHO968 product has performed well, becoming the only ADCC-enhanced anti-HER2 antibody modified by removing fucose in China and the world. Currently in phase II/III clinical stage, it is used to treat 1LHER2+ advanced CRC and 1LHER2+ advanced BTC; the company's IAPO971 is the fastest clinically advanced IL-15-based antibody cytokine in the world, potentially targeting various tumor types that overexpress PD-L1; there is currently no IL-10-based immunity The therapy has been approved to treat cancer, and the company's IAE0972 is in phase II clinical phase. It is the IL-10-based antibody cytokine with the fastest clinical progression in the world. It can potentially be used to treat various advanced tumors, including 2L head and neck squamous cell carcinoma, 3LCRC, 1L hepatocellular carcinoma, and 2L squamous NSCLC.
Risk warning
Uncertain results: The global biologics market continues to evolve, and the company needs to keep up with new technologies and methods to maintain a competitive position. Therefore, the company plans to continue to improve its technical capabilities in drug discovery, development and production. The company cannot guarantee that it can develop, improve or adopt new technologies and methods in a timely and cost-effective manner, successfully identify new technology opportunities, develop and launch new drugs or innovative drugs on the market, so that any patents or other intellectual property rights relating to new drugs or innovative drugs are fully protected or obtain the regulatory approval required for the relevant drug. Failure to act in this way may cause the company's technology to become obsolete, thereby harming the company's business and prospects.
Fierce competition in the industry: Companies face intense competition, and competitors may discover, develop, and commercialize competitive drugs earlier, which may adversely affect the company's ability to successfully commercialize drug candidates. Some of the company's competitors have more financial, technical and human resources, more mature commercialization infrastructure, and more drug candidates in late-stage clinical development. Even if the company's drug candidates are successfully developed and subsequently approved by the National Drug Administration, FDA, or other similar regulators, they will still face competition in other factors such as safety, efficacy, tolerability, and the timing and scope of regulatory approval.
Edited by Irene